Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Sees Large Decline in Short Interest

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) saw a large decline in short interest in February. As of February 15th, there was short interest totalling 54,300 shares, a decline of 17.4% from the January 31st total of 65,700 shares. Currently, 3.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 24,500 shares, the short-interest ratio is currently 2.2 days.

Alaunos Therapeutics Trading Down 1.6 %

NASDAQ:TCRT opened at $1.51 on Friday. Alaunos Therapeutics has a 12 month low of $1.48 and a 12 month high of $20.30. The stock has a 50 day moving average of $1.72 and a two-hundred day moving average of $2.17.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.